On October 21, 2025, Avadel Pharmaceuticals PLC's subsidiary settled lawsuits with Jazz Pharmaceuticals, receiving a $90 million payment and agreeing to royalties on their drug LUMRYZ. This event is significant for the company as it resolves ongoing litigation and establishes future financial obligations.